


## Dual-Action Organoplatinum Polymeric Nanoparticles Overcoming Drug Resistance in Ovarian Cancer


Amarasooriya M. D. S. Jayawardhanaa,<sup>a</sup> Zhihan Qiu,<sup>a</sup> Susan Kempf,<sup>a</sup> Han Wang,<sup>a</sup> Mitchell Miterko,<sup>a</sup> David J. Bowers,<sup>a</sup> and Yao-Rong Zheng<sup>\*a</sup>

a. Department of Chemistry and Biochemistry, Kent State University, 224 Williams Hall, Kent, Ohio 44242.


\* Corresponding author. Email: [yzheng7@kent.edu](mailto:yzheng7@kent.edu)




**Fig S1.** Representative TEM images of OPNPs.




**Fig S2.** DLS of OPNPs in PBS.




**Fig S3.** Cellular uptake of cisplatin and OPNPs in A2780cis.




**Fig S4.** <sup>31</sup>P {<sup>1</sup>H} NMR spectra of Compound **1** and the product (**3**) from the mixture of Compound **1** and guanine in DMSO-d<sub>6</sub> at r.t..



**Fig S5.** <sup>1</sup>H NMR spectra of Compound **1** and the product (**3**) from the mixture of Compound **1** and guanine in DMSO-d<sub>6</sub> at r.t..



**Fig S6.** ESI-MS spectrum of the product (**3**) from the mixture of Compound **1** and guanine.



**Fig S7.** Flow cytometric analysis of apoptic events in A2780cis cells treated with cisplatin or OPNPs for 72 h.